Abstracts tagged "spondyloarthritis"

Abstract Number: 0852 • ACR Convergence 2022
Development, Refinement and Weighting of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
Pamela Weiss¹, Timothy Brandon², Amita Aggarwal³, Ruben Burgos vargas⁴, Robert Colbert⁵, Gerd Horneff⁶, Rik Joos⁷, Ronald Laxer⁸, Kirsten Minden⁹, Angelo Ravelli¹⁰, Nicola Ruperto¹¹, Judith Smith¹², Matthew Stoll¹³, Shirley Tse⁸, Filip Van den bosch¹⁴, Walter P Maksymowych¹⁵, Robert G Lambert¹⁶, David Biko¹⁷, Nancy Chauvin¹⁸, Michael Francavilla¹⁷, Jacob Jaremko¹⁶, Nele Herregods¹⁹, Ozgur Kasapcopur²⁰, Mehmet YILDIZ²¹ and Alison Hendry²², ¹Children's Hospital of Philadelphia, Glen Mills, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁴hospital general de mexico, Ciudad de México, Mexico, ⁵NIH/NIAMS, Bethesda, MD, ⁶Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁷Ghent University Hospital, Basel, Switzerland, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁹Charité Universitätsmedizin Berlin, Berlin, Germany, ¹⁰Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Italy,Scientific Direction, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹¹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹²University of Wisconsin, Madison, WI, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ¹⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ¹⁶University of Alberta, Edmonton, AB, Canada, ¹⁷University of Pennsylvania, Philadelphia, PA, ¹⁸Penn State Health, Hershey, PA, ¹⁹Ghent University Hospital, Ghent, Belgium, ²⁰Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, ²¹Istanbul University-Cerrahpaşa, Istanbul, Turkey, ²²Middlemore Hospital, Auckland
Background/Purpose: The lack of classification criteria for axial disease hinders the conduct of clinical trials for juvenile spondyloarthritis (JSpA). We aimed to develop candidate classification…
Abstract Number: 1042 • ACR Convergence 2022
Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis
Atul Deodhar¹, Andrew Blauvelt², Sergio Schwartzman³, Carlo Salvarani⁴, Meghan Feely⁵, Andris Kronbergs⁵, Nadia Eberhart⁶, Danting Zhu⁵, Elsa Mevel⁵, Thorsten Holzkämper⁵, Eswar Krishnan⁷, Mark Lebwohl⁸, Proton Rahman⁹ and Helena Marzo-Ortega¹⁰, ¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ²Oregon Medical Research Center, Portland, OR, USA, Portland, OR, ³72nd Street Medical Associates, Scarsdale, NY, ⁴University of Reggio Emilia, Reggio Emilia, Italy, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Eli Lilly and Company, Vienna, Austria, ⁷Eli Lilly and Company, Carmel, IN, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Memorial University, St. John's, NL, Canada, ¹⁰Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom
Background/Purpose: Ixekizumab (IXE) is a high-affinity, monoclonal antibody targeting IL-17A and is approved for the treatment of psoriasis (PsO), psoriatic arthritis (PsA), ankylosing spondylitis (AS),…
Abstract Number: 1256 • ACR Convergence 2022
A Machine Learning Pipeline for Prediction of Bone Marrow Oedema Along the Sacroiliac Joints on Magnetic Resonance Imaging
Joris Roels¹, Ann-Sophie Kathleen De Craemer², Thomas Renson³, Manouk de Hooge⁴, Arne Gevaert¹, Lennart Jans³, Nele Herregods³, Thomas Van Den Berghe³, Philippe Carron³, Filip Van den bosch⁵, Yvan Saeys¹ and Dirk Elewaut⁶, ¹Center for Inflammation Research, UGent-VIB, Ghent, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Ghent University Hospital, Ghent, Belgium, ⁴Ghent University Hospital, Luxembourg, Luxembourg, ⁵Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁶Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium
Background/Purpose: Detection and semi-quantitative assessment of bone marrow oedema (BMO) on magnetic resonance imaging (MRI) of the sacroiliac (SI) joints is essential for the diagnosis…
Abstract Number: 1598 • ACR Convergence 2022
Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Philip J Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Jeffrey Neal⁶, Marleen Nys⁷, Tom Lehman⁷, Nikolay Delev⁷, Shimon Korish⁷, Miroslawa Nowak⁷ and Subhashis Banerjee⁷, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis Center of Lexington, University of Kentucky School of Medicine, Lexington, KY, ⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2) that acts by binding to the unique TYK2 regulatory domain,…
Abstract Number: 2136 • ACR Convergence 2022
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components
Arthur Kavanaugh¹, Laura Coates², Joseph Merola³, Philip J Mease⁴, Miroslawa Nowak⁵, Subhashis Banerjee⁵, Lauren Hippeli⁵ and Tom Lehman⁵, ¹University of California San Diego, La Jolla, CA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase in the Janus kinase (JAK) family that mediates the signaling of multiple cytokines, including those central…
Abstract Number: 0381 • ACR Convergence 2022
Most Disease Outcome Measures but Not ASDAS Are Influenced by Gender in Patients with Axial SpA: Results from ASAS-PerSpA
Diego Benavent¹, Dafne Capelusnik², Sofia Ramiro³, Anna Molto⁴, Clementina Lopez-Medina⁵, Maxime Dougados⁶ and Victoria Navarro-Compán⁷, ¹La Paz University Hospital, Madrid, Spain, ²Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France, ⁵Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ⁶Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁷Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: There is growing evidence revealing that females report worse patient-reported outcomes compared to males in axial spondyloarthritis (axSpA). However, in which precise outcomes there…
Abstract Number: 0416 • ACR Convergence 2022
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Casper Webers¹, Augusta Ortolan², Alexandre Sepriano³, Louise Falzon⁴, Xenofon Baraliakos⁵, Robert Landewé⁶, Sofia Ramiro⁷, Désirée van der Heijde⁸ and Elena Nikiphorou⁹, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²University of Padova/Leiden University Medical Center, Padova, Italy, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁹Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Since the 2016 update of the management recommendations for axial spondyloarthritis (axSpA), new evidence has emerged on the efficacy and safety of biological disease-modifying…
Abstract Number: 0853 • ACR Convergence 2022
Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?
Walter P Maksymowych¹, Nisha Varma², Arthur Meyers³, Jennifer Stimec⁴, Nikolay Tzaribachev⁵, Jonathan Akikusa⁶, Tarimobo Otobo⁴, Marion von Rossum⁷, Andrea Doria⁴ and Nele Herregods⁸, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Paediatric Radiology, The Royal Children's Hospital Melbourne, Melbourne, Australia, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Department of Diagnostic Imaging, SickKids, University of Toronto, Toronto, ON, Canada, ⁵PRI Research Institute, Bad Bramstedt, Germany, ⁶Rheumatology Service, Royal Children’s Hospital, Melbourne, Melbourne, Australia, ⁷Emma Children’s Hospital, Dept Pediatrics, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Ghent University Hospital, Ghent, Belgium
Background/Purpose: The evaluation of the sacroiliac joints (SIJ) in children with Juvenile Idiopathic Arthritis (JIA) increasingly relies on the use of MRI since radiography is…
Abstract Number: 1043 • ACR Convergence 2022
Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
Jan Brandt-Juergens¹, Martin Rudwaleit², Frank Behrens³, Christopher Ritchlin⁴, Daniel Peterlik⁵, Erhard Quebe-Fehling⁶, Renato Calheiros⁷ and Atul Deodhar⁸, ¹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ²University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ³Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁴Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corp., Hoboken, NJ, ⁸Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Uveitis is one of the most frequently reported extra-musculoskeletal manifestations of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1,2 The prevalence of anterior uveitis is…
Abstract Number: 1258 • ACR Convergence 2022
Development of International Consensus on a Standardized Image Acquisition Protocol for Diagnostic Evaluation of the Sacroiliac Joints by MRI – an ASAS-SPARTAN Collaboration
Robert G Lambert¹, Xenofon Baraliakos², Stephanie Bernard³, John Carrino⁴, Torsten Diekhoff⁵, Iris Eshed⁶, Kay-Geert Hermann⁷, Nele Herregods⁸, Jacob Jaremko¹, Lennart Jans⁸, Anne Jurik⁹, John O'Neill¹⁰, Monique Reijnierse¹¹, Michael Tuite¹² and Walter P Maksymowych¹³, ¹University of Alberta, Edmonton, AB, Canada, ²Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ³Brooke Army Medical Center, Fort Sam Houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sheba Medical Center, Tel Aviv, Israel, ⁷Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Aarhus University Hospital, Aarhus, Denmark, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹Leiden University Medical Center, Leiden, Netherlands, ¹²University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹³Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: In 2009, ASAS published a 'Definition of active sacroiliitis on MRI for classification of axial spondyloarthritis (axSpA)'. This definition relied on two MRI sequences…
Abstract Number: 1599 • ACR Convergence 2022
Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Joseph Merola¹, Robert Landewé², Iain B McInnes³, Philip J Mease⁴, Christopher Ritchlin⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Frank Behrens⁸, Dafna Gladman⁹, Laure Gossec¹⁰, Richard Warren¹¹, Barbara Ink¹², Deepak Assudani¹², Rajan Bajracharya¹², Jason Coarse¹³ and Laura Coates¹⁴, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Center, Meerssen, Netherlands, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁰Sorbonne Université, Paris, France, ¹¹The University of Manchester, Manchester, United Kingdom, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. The phase 3 BE COMPLETE study assessed the efficacy…
Abstract Number: 2196 • ACR Convergence 2022
Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System
Philip J Mease¹, Qi Wei², Michael Chiorean¹, Lulu Iles-Shih¹, Wanessa Matos², Andrew Baumgartner², Sevda Molani², Yeon Mi Hwang², Basazin Belhu² and Jennifer Hadlock², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Institute for Systems Biology, Seattle, WA
Background/Purpose: Reported infection rates and severe outcomes of COVID-19 in patients with immune-mediated inflammatory diseases (IMIDs) and their therapy, have varied depending on the nature…
Abstract Number: 0382 • ACR Convergence 2022
Factors Associated with Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability
Gregory McDermott¹, Faith Selzer¹, Sizheng Zhao², Joerg Ermann³ and Jeffrey Katz¹, ¹Brigham and Women's Hospital, Boston, MA, ²University of Manchester, Liverpool, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with axial spondyloarthritis (axSpA) experience significant delay between symptom onset and diagnosis. Determinants of delay are incompletely understood. We investigated the associations between…
Abstract Number: 0417 • ACR Convergence 2022
Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review
Dafne Capelusnik¹, Diego Benavent², Désirée van der Heijde³, Robert Landewé⁴, Denis Poddubnyy⁵, Astrid van Tubergen⁶, Louise Falzon⁷, Victoria Navarro-Compán⁸ and Sofia Ramiro⁹, ¹Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ²La Paz University Hospital, Madrid, Spain, ³Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Maastricht UMC+, Maastricht, Netherlands, ⁷Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁸Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The ASAS-SPEAR (SPondyloarthritis EARly definition) project aims to develop a consensual definition of early SpA. Therefore, it is important to know whether treatment earlier…
Abstract Number: 0857 • ACR Convergence 2022
Consensus-Driven Definition for Unequivocal Sacroiliitis on Radiographs for Classification in Juvenile Spondyloarthritis
Pamela Weiss¹, Timothy Brandon², Robert G Lambert³, David Biko⁴, Nancy Chauvin⁵, Michael Francavilla⁴, Nele Herregods⁶, Alison Hendry⁷ and Walter P Maksymowych⁸, ¹Children's Hospital of Philadelphia, Glen Mills, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Alberta, Edmonton, AB, Canada, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Penn State Health, Hershey, PA, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Middlemore Hospital, Auckland, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Radiographs are neither sensitive nor reliable in assessment of axial disease in juvenile spondyloarthritis (JSpA). However, they are still performed in some areas due…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].